Supplementary Figure S3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
Year: 2025
Type: supplementary-materials
Abstract: Pharmacokinetic exposure versus toxicity/response. (A) Steady-state plasma levels of TP-0903 parent drug in non-responders and responders (CR, CRh, CRi, MLFS). Percent decrease in (B) absolute neutrophil count (ANC) or (C) platelets in patients with a steady state plasma level above or below the median.
Authors: Eric D. Eisenmann, Ronan Swords, Ying Huang, Shelley Orwick, Daelynn Buelow, Nicole Abbott, Mitch Phelps, Joshua Zeidner, Matthew C. Foster, Tara L. Lin, Maria R. Baer, Yazan F. Madanat, Tibor Kovacsovics, Robert Redner, Zeina Al-Mansour, Bhavana Bhatnagar, Mona Stefanos, Molly Martycz, Franchesca Druggan, Timothy L. Chen, Ashley O. Yocum, Uma Borate, Brian J. Druker, Amy Burd, Ross L. Levine, John C. Byrd, Sharyn D. Baker, Alice S. Mims
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4413451242